

Almirall opens new call for proposals to better understand key pathological mechanisms of several skin diseases

- The new AlmirallShare call focuses on exploring partnerships to identify and investigate common pathological mechanisms and pathways translatable to skin diseases such as atopic dermatitis, hidradenitis suppurativa and vitiligo
- Scientists affiliated with universities, research centers, start-ups, biotech, and pharmaceutical companies worldwide can submit their proposals until 31st January, 2024
- Since its launch, the company's open innovation R&D platform has captured the attention of more than 1,100 scientists and received around 600 proposals from over 60 countries
- Recently, Almirall signed a collaboration with the Centre for Genomic Regulation (CRG) resulting from the latest AlmirallShare call for proposals

BARCELONA, Spain. 24th October, 2023 – **Almirall S.A. (BME:ALM)**, a global biopharmaceutical company focused on medical dermatology, today launched its eighth call through AlmirallShare, its open innovation platform, to identify research projects focused on key pathological mechanisms that can be the basis of innovative therapies for the treatment of skin diseases.

Almirall's objective through this call is **to identify and explore**, through collaboration with external partners, **common pathological mechanisms and pathways** that can drive disease in different organs and tissues and can be **translatable to dermatological diseases of interest**. Potential conditions include atopic dermatitis, hidradenitis suppurativa, and vitiligo, among others.

Scientists affiliated to universities, research centres, start-ups, biotechnology, and pharmaceutical companies from all over the world can submit their proposals at sharedinnovation.almirall.com until **January 31, 2024**. A team of Almirall scientific experts will evaluate the proposals submitted to select those that best meet the requirements of the call and have the potential to form a long-term business partnership with the company.

"Through AlmirallShare, we have secured valuable collaborations that reinforce our internal efforts to improve the lives of people with skin diseases. This year we are going one step further by focusing on understanding the key pathological mechanisms that drive skin diseases. We encourage scientists from all disciplines to participate in this call, which follows a holistic approach that goes beyond dermatology," stated **Maribel Crespo, AlmirallShare Leader**.

Below are listed key mechanisms identified and the dermatological diseases in which they could play a key role.

Disease mechanism/pathway Skin examples	Potential disease application
New pathways that promote epithelial (epidermal) repair Cytokine stimulation of epidermis	Atopic dermatitis Hidradenitis suppurativa
Therapeutically targeting glycosylation/sialylation of IgE Mast cell sensitization	Chronic urticaria Food allergy

Mechanism(s) by which sweat and/or sebum trigger tissue inflammation Microbial or viral infection of sweat glands.	Hidradenitis suppurativa
Understanding the role of type II immunity in regulation of tissue/stem cell homeostasis Removal/depletion or repopulation of melanocytes in vitiligo	Vitiligo
Mechanisms by which environment induced stress of epithelial cells that drives immune activation Melanocyte stress and subsequent immune activation in vitiligo	Vitiligo
Mechanisms by which the tissue environment controls development/activation of type 2 T cells in the skin and other tissues IL33 activation of T cells	Atopic dermatitis
Non-cytotoxic mechanisms by which epithelial associated cells are targeted/removed in disease Melanocytes in epidermis of vitiligo patients	Vitiligo
Mechanisms driving tissue immune privilege collapse Hair follicles in alopecia	Alopecia

AlmirallShare, driving collaborative research in medical dermatology

AlmirallShare was launched in 2017 as an open innovation R&D platform designed to **facilitate collaborations in dermatological research and find innovative solutions in medical dermatology**. This initiative has drawn more than 1,100 scientists and received around 600 proposals from over 60 countries, proving to be a successful initiative that has allowed Almirall to gain increasing recognition from the scientific community, raising the company's profile as a trusted partner for future collaborations.

Through this unique platform, the company has established valuable collaborations with research centres, universities, public and private institutions, hospitals, and biotech companies. To date, **the company has established eight collaborative projects with different institutions**, including collaborations for new therapies (IDIBAPS, University of Turin, University of South Australia, Hospital de la Santa Creu i Sant Pau), new targets (Dublin City University, University of Namur) and new preclinical models (University College Dublin, University of Sheffield).

The most recent **collaboration, resulting from the latest AlmirallShare call for proposals, is with the Centre for Genomic Regulation (CRG)**. This partnership aims to develop and characterize novel preclinical models for identifying new treatments for non-melanoma skin cancer (NMSC). The goal is to establish experimental models that allow the identification and/or validation of novel therapeutic approaches and the evaluation of new drugs for these diseases. **Anabel Sanz, Head of Technology and Business Development at CRG**, reflected on the importance of this collaboration: *"At CRG, we establish partnerships with industry to solve real-world problems. Thanks to AlmirallShare, we are forging a solid collaboration with Almirall, sharing experiences and knowledge, and leveraging each other's strengths to ultimately offer treatment options for the patients in need."*

About Almirall

Almirall is a global biopharmaceutical company focused on medical dermatology. We collaborate with scientists and healthcare professionals to address patients' needs through science to improve their lives. Our Noble Purpose is at the core of our work: "Transform the patients' world by helping them realize their hopes and dreams for a healthy life". We invest in differentiated and ground-breaking medical dermatology products to bring our innovative solutions to patients in need.

The company, founded in 1944 and headquartered in Barcelona, is publicly traded on the Spanish Stock Exchange (ticker: ALM). Throughout its 79-year history, Almirall has focused intensely on patients' needs. Almirall has a direct presence in 21 countries and strategic agreements in over 70, with about 1,800 employees. Total revenue in 2022 was €878.5MM.

For more information, please visit www.almirall.com

Media contact Almirall

Tinkle
Laura Blázquez
lblazquez@tinkle.es
Phone: (+34) 600 430 581

Investors' Relations contact

Almirall
Pablo Divasson del Fraile
pablo.divasson@almirall.com
Phone: (+34) 93 291 3087

Corporate Communications contact

Almirall
Mar Ramírez
mar.ramirez@almirall.com
Phone: (+34) 659 614 173

Legal warning

This document includes only summary information and is not intended to be exhaustive. The facts, figures and opinions contained in this document, in addition to the historical ones, are "forward-looking statements". These statements are based on the information currently available and the best estimates and assumptions that the company considers reasonable. These statements involve risks and uncertainties beyond the control of the company. Therefore, actual results may differ materially from those declared by such forward-looking statements. The company expressly waives any obligation to revise or update any forward-looking statements, goals or estimates contained in this document to reflect any changes in the assumptions, events or circumstances on which such forward-looking statements are based, unless required by the applicable law.